Navigation

NHS organisations to be named in report into the uptake of NICE-approved drugs on the NHS

8040890-article-medicine-cupNHS organisations will, for the first time, be named in this year's report on the uptake of NICE-approved drugs on the NHS in England, to be published in November.

The report will compare the actual use of medicines that have been positively appraised by NICE with an estimate calculated by the Institute.

It will name the NHS organisations involved, with data shown at Strategic Health Authority (SHA), Primary Care Trust (PCT) or cancer network level, depending on the level of usage and healthcare settings.

It is the second report concerning the uptake of medicines that have been positively appraised by NICE, and follows on from the first report published in September 2009.

The first report was developed by the Department of Health, the Association of the British Pharmaceutical Industry (ABPI), NICE and the NHS Information Centre, as part of a commitment in the Pharmaceutical Price Regulation Scheme (PPRS) agreement to publish an annual report detailing the use of NICE-appraised medicines.

A total of 26 different treatments, covering 13 technology appraisals, were included in the first report. Treatments were for a wide range of conditions, including Alzheimer's disease, osteoporosis and obesity.

Out of the 12 appraisals where a comparison could be made, observed use by the NHS in England was higher than the predicted use for 7 appraisals and lower for 5.

Currently, 81 medicines are being considered for inclusion in this year's report, which considers usage during 2009. However, it is likely that some these medicines will not be included because of a lack of quality data.

There will be a number of improvements in this year's report;

  • Updating of estimates of eligible patients which are derived from NICE costing templates, where possible.
  • Improved methodologies
  • An opportunity for manufacturers to provide information to support the estimate development
  • An opportunity for manufacturers to aid the validation of usage data.

NICE is keen to hear from prescribing leads, relevant PCT and SHA managers on the approach being taken in this year's report and how this information could be utilised by the NHS.

Please send your comments to Tom.Conyers@nice.org.uk

20 August 2010

This page was last updated: 20 August 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.